{'fraction_non_alphanumeric': 0.025688073394495414, 'fraction_numerical': 0.003669724770642202, 'mean_word_length': 5.204545454545454, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Antidepressant augmentation: good news, limitations, and stumbling blocks.

Dr Zhou and colleagues have done an excellent job of reviewing and analyzing the world's literature on the efficacy and tolerability of pharmacologic agents used to augment antidepressants in treatment-resistant unipolar major depression. It seems we have some good news, but a lot remains to be accomplished. The good news is that several agents were found to have significant efficacy in terms of response (4 agents) and remission (6 agents) in comparison to placebo.